Investors

Corporate Profile

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of our first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have disease-modifying activity through the suppression of malignant progenitor cell clone proliferation, which allows potential recovery of normal hematopoiesis. 

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. 

Ongoing clinical studies of imetelstat consist of IMerge™, a Phase 2/3 trial in lower risk myelodysplastic syndromes (MDS) and IMbark™, a Phase 2 trial in Intermediate-2 or High-risk myelofibrosis.

Recent News

Date Title and Summary  
Toggle Summary Studies Show Geron´s Stem Cell Therapeutic for Spinal Cord Injury Produces Nerve Growth Factors
Findings Published in Stem Cells and Development Indicate GRNOPC1 Promotes Survival and Regeneration of Neurons Damaged During Spinal Cord Injury MENLO PARK, Calif., Jan. 17, 2007 – Geron Corporation (Nasdaq: GERN) today reported that studies show GRNOPC1, the company’s human embryonic stem cell
Toggle Summary Geron Corporation to Present at BIO CEO & Investor Conference
MENLO PARK, Calif., Feb. 9, 2007 – Geron Corporation (Nasdaq: GERN) will present an update of the company’s product development programs at 1:15 p.m. ET on Monday, Feb. 12, 2007, at the BIO CEO & Investor Conference in New York City. The update of Geron’s portfolio of telomerase–based anti–cancer
Toggle Summary Unique Structure of Geron´s Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity in Lung Cancer Cells
MENLO PARK, Calif., Feb. 15, 2007 – Geron Corporation (Nasdaq: GERN) today announced the publication of preclinical data that show specific structural elements of GRN163L contribute to its unique anti–tumor and anti–metastatic activity. Published in Cancer Research (2007; 67: 1121–29), the studies

Upcoming Events

More >>
There are currently no events to display.

Corporate Presentation

Documents

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Contact Information

CG Capital
877-889-1972

investor@geron.com